## CONTENTS

BIA Corporate Sponsors .......................................................... 4

Programme ............................................................................. 5

Session 1: Abstracts .............................................................. 6

Session 2: Abstracts .............................................................. 7

Session 3: Abstracts .............................................................. 8

Session 4: Abstracts .............................................................. 10

Speaker Biographies ............................................................. 11

Meet the Expert Sessions at FIS .......................................... 14

NITCAR at FIS ..................................................................... 15

9th HIV Dilemmas ............................................................... 16

Trainee Membership and Trainee Representatives ............... 17

Notes Pages ........................................................................ 18
ViiV Healthcare aims to take a deeper and broader interest in HIV/AIDS than any company has done before and takes a new approach to deliver effective and new HIV medicines, as well as support communities affected by HIV. For more information on the company, its management, portfolio, pipeline, and commitment, please visit www.viivhealthcare.com.

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of R&D to delivering products and solutions to people with skin conditions. Within dermatology LEO delivers solutions for actinic keratosis, psoriasis, eczema and skin infections. LEO Pharma also provides treatments for thrombosis (blood clotting). LEO Pharma UK/Ireland is also committed delivering high quality patient care through partnerships and the provision of comprehensive patient support and educational resources.

Eumedica is an independent pharmaceutical company specialising in the production and distribution of niche hospital products. We aim to ensure development and continuity of care for patients with serious, even rare diseases. Eumedica currently operates in several therapeutic areas including the infectiology, haematology, anaesthesiology, obstetrics, gastro-enterology and psychiatry.
Programme

Chaired by: Maheshi Ramasamy & Rajeka Lazarus

09.00  Registration & coffee

Session 1:

09.25  Welcome

09.30  Meliodosis  
        Dr Susanna Dunachie  
        University of Oxford

10.15  Hepatitis B  
        Dr Monique Andersson  
        Oxford University Hospital,  
        University of Stellenbosch,  
        Cape Town, South Africa

11.00  Coffee

Session 2:

11.15  Update on EUCAST susceptibility testing  
        Dr Mandy Wootton  
        Public Health Wales

12.00  Interactive clinical cases  
        Dr Nick Beeching  
        Liverpool School of Tropical Medicine

12.45  Lunch

Session 3:

13.30  New guidelines for hepatitis C  
        Dr Peter Moss  
        Hull & East Yorkshire Hospitals NHS Trust

14.15  Out of programme experience  
        Dr Emily Wise,  
        MSF  
        Dr Kate Woods,  
        PHE in Laos  
        Dr Rajeka Lazarus,  
        Singapore

15.00  Coffee

Session 4:

15.20  Antifungal agents - what, when and how  
        Dr Eavan Muldoon  
        National Aspergillosis Centre  
        Manchester

16.05  Clinical molecular microbiology  
        Dr John Hartley  
        Great Ormond Street Hospital  
        London

16.50  Meeting close
### Session 1:

**Title**  
Melioidosis

**Author**  
Dr Susanna Dunachie

**Address**  
University of Oxford

---

**Abstract**

Melioidosis is sepsis illness caused by the Gram negative bacterium *Burkholderia pseudomallei*. This environmental pseudomonad is found in tropical paddy fields and classically causes disease in rice farmers with diabetes. Melioidosis has long been recognised as a significant cause of morbidity and death in Northeast Thailand, surrounding regions and in Northern Australia. It is now known to be a grossly neglected disease in many countries across the tropics including India, Bangladesh and parts of Africa and South America. Increased recognition alongside the rise in prevalence of diabetes mellitus, the increasing age of rice farmers and changing land-use patterns are likely to lead to an increase in importance of this pathogen in the future.

The commonest clinical presentation of melioidosis is pneumonia and septic shock, but a wide range of presentations occur including abscess formation, bone and joint infection, CNS involvement and chronic forms showing latency and relapse. The majority of patients have an evident degree of immune compromise, with risk factors including diabetes mellitus, renal disease, hazardous alcohol consumption and old age. In-hospital mortality in Thailand is around 40% of culture confirmed cases. The gold standard for diagnosis is culture of the bacterium, and confirmation of diagnosis is difficult in areas that lack microbiology culture facilities. The bacterium is intrinsically resistant to many first-line antibiotics including gentamicin, and successful treatment requires good supportive care and a long course of intravenous ceftazidime or a carbapenem followed by oral follow-on therapy.

This talk will give an overview of melioidosis world-wide for doctors specialising in infectious diseases and microbiology.

---

**Title**  
Hepatitis B

**Author**  
Dr Monique Andersson

**Address**  
Oxford University Hospital, University of Stellenbosch, Cape Town, South Africa

---

Chronic hepatitis B affects around 240 million people world wide, yet a safe and effective vaccine has been available for more than 20 years. The virology and immunology of HBV is complex and explain the prevalence of this infection. International guidelines for HBV therapy differ and treatment strategies continue to evolve. HBsAg seroconversion remains elusive. Long term suppressive therapy is the mainstay of treatment, although drug resistance, whilst uncommon is problematic. Interferon has limited use, poor response rates and an unacceptable side effect profile. Preventing infection is important - with HBV MTCT a priority. Strategies to prevent HBV MTCT are available, but depend on effective screening and management of pregnant women. HBV cure will speed up the prospect of eradication of this infection. Numerous strategies have been proposed, but research is still in the early stages of development.
Title: Update on EUCAST susceptibility testing
Author: Dr Mandy Wootton
Address: Public Health Wales

Abstract
Antimicrobials are the most commonly used drugs in both hospitals and community. Knowledge of resistance or susceptibility of infecting pathogens to antimicrobials is fundamental to effective patient treatment. Antimicrobial susceptibility testing in laboratories around the UK has been performed using the British Society for Antimicrobial Chemotherapy (BSAC) disc diffusion method for the past 15 years. As of January 2016 the BSAC is ceasing support for the BSAC disc diffusion method and recommends adoption of the European Committee on Antimicrobial Susceptibility Testing (EUCAST) disc diffusion method. Does different methodology mean different results and how does this impact those who use the results?

Title: Interactive clinical cases
Author: Dr Nick Beeching
Address: Liverpool School of Tropical Medicine

Abstract
The session will consist of several interactive case presentations of patients with infections related to recent travel. The aim of the session is to highlight key diagnostic and management issues raised by these patients, and to indicate appropriate sources of information for further learning.
Title: New guidelines for hepatitis C
Author: Dr Peter Moss
Address: Hull & East Yorkshire Hospitals NHS Trust

Abstract
The past 4 years have seen dramatic changes in the way that we can treat chronic hepatitis C infection. After more than 20 years of using interferon-based immunotherapy, with limited efficacy and significant adverse effects, the first direct acting antiviral (DAA) drugs for treating hepatitis C were licensed in 2011. Four years later there are 13 DAAs licensed, with many more in late stages of development. Sustained viral response rates have gone from 50% to >90%, with shorter treatment courses, all oral regimens, and fewer adverse events. There is now a realistic possibility of curing the majority of people who have access to the new drugs. However significant challenges remain. In most countries there is limited access to these expensive new treatments. Some groups of patients remain more difficult to cure, and there is a risk of resistant viruses emerging. This talk describes the drug regimens currently and imminently available in England, and discusses the future provision of hepatitis C services in this country.

Title: Out of programme experience
Author: Dr Emily Wise
Address: Médecins Sans Frontières (MSF)

Abstract
I will discuss volunteering overseas for a humanitarian aid organisation, in particular Medecins Sans Frontieres (MSF), and how MSF is distinct from other charities. I will cover details of my MSF mission including the medical work and aspects of working in a challenging environment. I will discuss the process of applying to work with MSF; desirable qualities in a volunteer; the pros, cons and personal sacrifices involved with such work; and how my placement has enhanced my career.
Title: Out of programme experience

Author: Dr Kate Woods

Address: PHE in Laos

Abstract

Based at Mahosot Hospital in the capital Vientiane the Public Health England - LOMWRU (Lao-Oxford-Mahosot-Wellcome Trust Research Unit) collaboration provides the perfect OOPE (or even OOPT/ OOPR) for a senior infectious diseases/ microbiology trainee interested in delivering a high quality infection service (both clinical liaison and laboratory based) in a resource constrained tropical setting. There is ample opportunity not only for clinical liaison but also for research, training of physicians and laboratory technicians, audit and management. Lao is a fascinating (if a little humid!) place to live and to work and LOMWRU sits within the wider MORU (Mahidol Oxford Tropical Medicine Research Unit) Tropical network providing opportunities for additional forays within the region.

Title: Out of programme experience

Author: Dr Rajeka Lazarus

Address: Singapore

Abstract

A year in Singapore doing infectious diseases and general medicine provided me with a broad range of clinical experience. In addition, working in a different health care system and culture provided a fresh perspective on how things can be done. This brief presentation will outline the reasons to go to Singapore, the spectrum of clinical experience available and how to go about it.
Antifungal agents - what, when and how

Dr Eavan Muldoon
National Aspergillosis Centre, Manchester

Abstract
Fungal infections are increasing in both relevance and prevalence in modern medicine. The management of these infections can be complex due to patient co-morbidities, drug toxicities and interactions. This session will be an overview of the currently available antifungals, and the considerations in initiation, continuation and monitoring of these agents.

Clinical molecular microbiology

Dr John Hartley
Great Ormond Street Hospital, London

Abstract
I will describe, compare and contrast the range of techniques we have routinely available and demonstrate how they can, or cannot yet, be incorporated into routine practice.
Dr Susanna Dunachie  
**University of Oxford**

Dr Dunachie is an infectious diseases physician with a research focus on characterising the immune response for vaccine development for tropical diseases including melioidosis, malaria and scrub typhus. After completing a PhD with Adrian Hill on malaria vaccine trials and immune correlates of protection using transcriptomal analysis, she completed her specialist training in infectious diseases and microbiology in Oxford. From 2011 until 2015 she was based at the Wellcome Trust-Mahidol University-Oxford Tropical Medicine Research Programme in Bangkok. She is now setting up a laboratory at the Peter Medawar Building for Pathogen Research in Oxford to support the ongoing Thai programme and to further explore the phenotype of the adaptive response to *B. pseudomallei*. Susanna holds an honorary consultant contract in Tropical Medicine and Infectious Diseases at Oxford University Hospitals NHS Trust.

---

Dr Monique Andersson  
**Oxford University Hospital, University of Stellenbosch, Cape Town, South Africa**

Dr Andersson is a Clinical Fellow Department of Microbiology and Infectious Diseases, Oxford University Hospitals, UK. She trained in Virology and Genitourinary Medicine in the UK before returning to South Africa in 2009 where she established a viral hepatitis research group based at Stellenbosch University. Her research interests include hepatitis B MTCT, HIV-HBV co-infection, hepatocellular carcinoma and hepatitis E virus infection.

---

Dr Mandy Wootton  
**Public Health Wales**

Dr Wootton is currently Head of the Specialist Antimicrobial Chemotherapy Unit in Cardiff. The laboratory provides an antibiotic resistance reference service for Wales and is the BSAC susceptibility testing laboratory for the UK, helping develop the EUCAST method. Prior to Cardiff she spent over 10 years in clinical research on antibiotics in Bristol, where she completed her PhD in glycopeptide resistance in *S. aureus*. She is secretary of the BSAC standing committee on susceptibility testing and contributed to the EUCAST subcommittee on resistance mechanisms.

---

Dr Nick Beeching  
**Liverpool School of Tropical Medicine**

Dr Beeching is a Senior Lecturer in Infectious Diseases at the Liverpool School of Tropical Medicine and Clinical Director of the Tropical and Infectious Disease Unit, Royal Liverpool University Hospital. He has long-standing clinical and research interests in imported and emerging infections and zoonoses, and much of his current research in this area is supported by the NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, a collaboration between the University of Liverpool, the Liverpool School of Tropical Medicine and Public Health England. He is the Liverpool lead for the national Imported Fever Service and past chair of the steering committee for the National Travel Health Network and Centre (NaTHNaC). He has co-authored over 200 peer reviewed publications and several books including 3 editions of Lecture Notes: Tropical Medicine.
Dr Peter Moss  
Hull & East Yorkshire Hospitals NHS Trust

Dr Moss is a Consultant in Infectious Diseases, specializing in the management of viral hepatitis, and is the Clinical Lead for the new HCV Operational Delivery Network covering North and East Yorkshire and northern Lincolnshire.

Dr Moss is Chair of the NHS England Specialised Services Clinical Reference Group for Infectious Diseases, and of the NHS England Commissioning Advisory Group on hepatitis C. He was a member of the national Expert Advisory Panel overseeing the early access programme for direct acting HCV anti-viral drugs in England. He also sits on the Department of Health Advisory Group on Hepatitis, and is the recent past President of the British Infection Association.

Dr Emily Wise  
Médecins Sans Frontières (MSF)

Dr Wise is a London Deanery Specialist Registrar in Infectious Diseases and General Internal Medicine. She studied medicine at Emmanuel College, Cambridge and Royal Free and University College London Medical School and has an MSc in Infectious Diseases from London School of Hygiene and Tropical Medicine (LSHTM). She has worked at multiple London hospitals as a SpR including UCLH/Hospital for Tropical Diseases, St Thomas’, St Mary’s and The Royal Free, including managing Ebola in the High Level Isolation Unit. In 2012 Emily took a year’s sabbatical to volunteer as a field doctor with Médecins Sans Frontières (MSF) in a multi-drug resistant tuberculosis (MDR-TB) programme in Karakalpakstan, Uzbekistan. Her work there included establishing a MDR-TB DOTSPlus programme in a new district, helping to establish a ‘short course regimen’ research pilot and producing research on MDR-TB culture reversion, which she went onto present at the 44th Union World Conference on Lung Health. Emily kept a field blog whilst working for MSF http://blogs.msf.org/en/staff/authors/emily-wise, which has been viewed in excess of 50,000 times and she has written several articles on her experiences with the organisation, including for The Guardian. She has spoken on MDR-TB at a vast array of forums including at several All-Party Parliamentary Groups in the Houses of Parliament. She has published on MDR-TB, cutaneous leishmaniasis, drug-resistant malaria and human African trypanosomiasis and has contributed chapters in textbooks on malaria and humanitarian work abroad. Emily has a keen interest in teaching and has been awarded a UCL Top Teacher Award. Her teaching roles have included being a course lecturer on both the LSHTM and East African Diplomas in Tropical Medicine and Hygiene, a UK Resus Advanced Life Support Instructor and a Royal Society of Medicine facilitator. Emily has fundraised over £5000 for MSF.

Dr Kate Woods  
PHE in Laos

Dr Woods is an Infectious Diseases/Microbiology Registrar (ST7) in London, currently working at the Royal Free Hospital. She spent just over a year on OOPE at the Lao-Oxford-Mahosot-Wellcome Trust Research Unit (LOMWRU) based in Mahosot Hospital, Vientiane, Lao PDR April 2014 - July 2015. Earlier in her registrar rotation she also took a year’s OOPE to work on the medical ward at Mbarara Regional Referral Hospital, Uganda October 2009 - September 2010. She has had the pleasure of returning to Uganda the last 3 years to facilitate a community placement based in Bwindi on the East Africa Diploma in Tropical Medicine and Hygiene. She has an interest in infection diagnostics and medical education in resource limited settings.

Website: http://www.tropmedres.ac/lomwru-laos
Dr Rajeka Lazarus  
Singapore  
Dr Lazarus is a Trainee in Microbiology and Infectious Disease in Oxford. She is an expert on out of programme experience as she has spent much time out of programme on maternity leave, in research as well as in Singapore. She is currently one of the BIA trainee representatives.

Dr Eavan Muldoon  
National Aspergillosis Centre, Manchester  
Dr Muldoon is a graduate of University College Dublin. She completed her Specialist Registrar training in Infectious Diseases and General Internal Medicine in the Republic of Ireland. Following this she traveled to the United States and completed a fellowship in Infectious Diseases in Tufts Medical Center, Boston, where she was the inaugural recipient of the Francis P. Tally Fellowship in Infectious Diseases and received the Kassaward for Clinical Excellence. She joined the National Aspergillosis Centre in August 2013.

She was awarded a Doctor of Medicine (MD) by Trinity College Dublin in 2011. Her thesis was entitled ‘Syphilis and HIV co-infection in Dublin; Strategies to enhance diagnosis, investigation and management’. She graduated from Tufts University, Boston with a Masters in Public Health in 2013.

Her clinical and research interests include antibiotic stewardship, outpatient parenteral antimicrobial therapy (OPAT) and transplant infectious diseases.

Dr John Hartley  
Great Ormond Street Hospital  
Dr Hartley has been a Consultant Microbiologist at Great Ormond Street Hospital for Children NHS Foundation Trust since 2000. He is involved in the development and implementation of molecular techniques for the diagnosis and control of infection.
Get answers to your questions........

The BIA are supporting a new event aimed at trainees at FIS 2015. The Meet the Expert sessions will give trainees the opportunity to speak to a senior member of the BIA about training and research issues.

The session will be run from the BIA stand located in exhibition hall (Stand D1). Trainees can sign up at the BIA stand for a 10 minute consultation with one of our experts.

**Session details:**

**Saturday 21st November**
13.00 to 13.45
Training Issues

*Expert:*

Dr Martin Wiselka BM BCh MA, MD, PhD, FRCP  
Consultant in Infectious Diseases and General Medicine, President of British Infection Association

**Sunday 22nd November**
13.00 to 13.45
Research Issues

*Experts:*

Prof David Dockrell MD FRCPI FRCP(Glas) FACP  
Professor of Infectious Diseases, Sheffield University

Prof Thomas Evans  
Professor of Molecular Microbiology, University of Glasgow

For further information please contact Rajeka Lazarus, BIA Trainee Representative  
rajeka@doctors.org.uk
NATIONAL INFECTION TRAINEE COLLABORATIVE FOR AUDIT AND RESEARCH (NITCAR) AT FIS 2015

NITCAR is a national network of Infection trainees working together on national infection projects.

Come & join us for nibbles and drinks at an informal meeting at The Crowne Plaza Hotel (attached to the conference centre using the link bridge) Island Suite - Barra Room on Sunday 22nd November between 5:15 and 6:30pm.

Find out more about how to get involved in a National infection project.
Be inspired by our inaugural project: HOODINI (Hospital onset diarrhoeal investigation).

Not at FIS?
Don’t miss out.
Join us at our next meeting:

Thursday 11th February 2016 from 10-3pm in Cambridge

We will be discussing new project proposals.

Want to know more?
Got an idea?

Contact us at NITcollaborative@gmail.com or http://nitcollaborative.wix.com/nitcar
Workshop In Infectious Diseases
9th HIV Dilemmas
Friday 29th January 2016
Manchester Conference Centre
78 Sackville Street, Manchester M1 3BB

Typical Topics Covered:
- Hepatitis and hepatitis co-infection
- Perinatal issues
- Multiple pathology in a single case
- Medical complications; bone, kidney, metabolic
- Transitional care for adolescents
- Ethical issues
- Sexually transmitted infections
- Complex ARV case
- Elderly HIV patients

Speakers To Include:
- Professor Rob Miller (London), Dr Nick Beeching (Liverpool),
  Dr Ed Wilkins (Manchester), Dr Mas Chaponda (Liverpool),
  Dr Leena Sathia (London)

A mixture of difficult and challenging cases are drawn from real life, all presented by experts using interactive keypad voting throughout.

Suitable for consultants and trainees from all specialities who look after people with HIV.

As in previous years, the focus will be on infections and other complications of HIV and its treatment, but will also include relevant aspects of antiretroviral therapy changes.

Previous meetings have been very highly rated and audience feedback is used to improve further.

Registration:
Early bird fee (until 18th December): £65.00
Standard fee (from 19th December): £95.00

Online registration available at www.hartleytaylor.co.uk

For further information please contact Aimee (aimee@hartleytaylor.co.uk or 01565 621967)
The BIA actively encourages the participation of trainees within the Society, with 3 trainee members being elected to the Council every two years. Their roles are overlapping with some specific responsibilities.

**Joint responsibilities:**

- Attend (up to) four council meetings a year, including one to coincide with the Spring Meeting of the BIA and one to take place at the Federation of Infection Societies Meeting in the winter.
- Contribute to and update the trainees’ section of the BIA website.

**Individual responsibilities:**

- Organise trainees’ meetings twice a year (Spring and Autumn)
- Responsibility for training issues including the following:
  - Attend meetings of the Infectious Diseases Specialist Advisory Committee (SAC) and Joint Committee for Infectious Diseases and Tropical Medicine Training meetings (4-6 per year).
  - Update trainees on relevant matters via the trainees’ e-mail list and to keep the list up to date.
  - Respond to any other training issues that arise.

Trainee members of the BIA have the option of free membership with benefits that include trainees’ meetings and the BIA newsletter.

The BIA trainee representative role is due for re-election next year with nominations to open in February 2016. Nomination forms will be available at the BIA Trainees’ Meeting, the BIA stand at FIS, on the trainees’ section of the BIA website [http://www.britishinfection.org/about-bia/officer-roles](http://www.britishinfection.org/about-bia/officer-roles) or by contacting:

- Rajeka Lazarus rajeka@doctors.org.uk
- Maheshi Ramasamy maheshi.ramasamy@ouh.nhs.uk

For further information please visit the trainees’ section of the British Infection Association website at: [www.britishinfection.org](http://www.britishinfection.org)